Document is current
Any future updates will be listed below
-
Authors
Kosunen, Mikko https://orcid.org/0000-0002-0908-5288
Ruotsalainen, Jarno https://orcid.org/0000-0003-1056-3838
Kallio, Alvar https://orcid.org/0009-0001-7269-0421
Metsä, Roope https://orcid.org/0009-0007-7342-5797
Raittinen, Paavo https://orcid.org/0000-0003-4207-8415
Lehmus, Leena https://orcid.org/0009-0004-0494-3900
Korhonen, Maarit J. https://orcid.org/0000-0002-2953-4757
Purmonen, Timo https://orcid.org/0000-0001-7794-7495
-
Funding
Funding for this research was provided by:
Pfizer Oy
- License Information
-
More Information
Article History
Accepted: 21 August 2024
First Online: 6 September 2024
Declarations
:
: The study was funded by Pfizer Oy.
: MK and LL are employed by Pfizer Oy and own Pfizer stocks. RM is a former employee of Pfizer Oy and owned Pfizer stocks at the time of this work. JR, AK, PR, MJK and TP are employees of Oriola Finland Oy, which received funding from Pfizer Oy in connection with the development of this manuscript.
: This article does not contain any studies with human participants performed by any of the authors. This register-based study was approved by each register holder.
: Not applicable.
: Not applicable.
: Research data are not shared. The data are available with the permission of The Finnish Social and Health Data Permit Authority. Thus, the data are not publicly available.
: The code used in the data management and analysis can be made available upon reasonable request to the authors.
: MK, JR, RM, LL, MJK and TP contributed to the study design and objectives, interpretation of results and revising the manuscript. AK and PR were responsible for data analysis. MK and JR were responsible for manuscript development. All authors have reviewed and approved the final version of the manuscript.
